BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 28710566)

  • 21. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
    Ali Abuderman AW; M Aldakheel F
    Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Translational research and diagnosis in GIST].
    Wardelmann E
    Pathologe; 2012 Nov; 33 Suppl 2():273-7. PubMed ID: 22968735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
    Zhi X; Zhou X; Wang W; Xu Z
    PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
    Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel germline KIT mutation (p.L576P) in a family presenting with juvenile onset of multiple gastrointestinal stromal tumors, skin hyperpigmentations, and esophageal stenosis.
    Neuhann TM; Mansmann V; Merkelbach-Bruse S; Klink B; Hellinger A; Höffkes HG; Wardelmann E; Schildhaus HU; Tinschert S
    Am J Surg Pathol; 2013 Jun; 37(6):898-905. PubMed ID: 23598963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation.
    Jones DH; Caracciolo JT; Hodul PJ; Strosberg JR; Coppola D; Bui MM
    Cancer Control; 2015 Jan; 22(1):102-8. PubMed ID: 25504284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.
    Miettinen M; Lasota J
    Arch Pathol Lab Med; 2006 Oct; 130(10):1466-78. PubMed ID: 17090188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
    Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Familial and multiple gastrointestinal stromal tumors with fair response to a half-dose of imatinib.
    Bamba S; Hirota S; Inatomi O; Ban H; Nishimura T; Shioya M; Imaeda H; Nishida A; Sasaki M; Murata S; Andoh A
    Intern Med; 2015; 54(7):759-64. PubMed ID: 25832938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del).
    Huss S; Künstlinger H; Wardelmann E; Kleine MA; Binot E; Merkelbach-Bruse S; Rüdiger T; Mittler J; Hartmann W; Büttner R; Schildhaus HU
    Mod Pathol; 2013 Jul; 26(7):1004-12. PubMed ID: 23599150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familial Gastrointestinal Stromal Tumor with Germline
    Sekido Y; Ohigashi S; Takahashi T; Hayashi N; Suzuki K; Hirota S
    Anticancer Res; 2017 Mar; 37(3):1425-1431. PubMed ID: 28314314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
    Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
    Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
    Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK
    Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
    Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
    JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
    Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
    Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment: A case report and diagnostic utility of ETV1 mRNA in situ hybridization.
    Jung M; Park SH; Jeon YK; Won JK; Yang HK; Kim WH
    Medicine (Baltimore); 2017 Dec; 96(49):e9031. PubMed ID: 29245294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.